Ogura Michinori | Department Of Hematology And Chemotherapy Aichi Cancer Center

スポンサーリンク

概要

関連著者

もっと見る

著作論文

Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas : Results of a Japanese Phase II Study
Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study
Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer : Japan Clinical Oncology Group study, JCOG 9208
Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
Primary Hepatic Follicular Lymphoma : A Case Report and Discussion of Chemotherapy and Favorable Outcomes
Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese
CD56/NCAM-Positive Langerhans Cell Sarcoma : A Clinicopathologic Study of 4 Cases
Phenotypic analysis of peripheral T/NK cell lymphoma : Study of 408 Japanese cases with special reference to their anatomical sites
Pilot Phase I/II Study of New Salvage Therapy(CHASE) for Refractory or Relapsed Malignant Lymphoma
CD34^+-Selected Autologous Peripheral Blood Stem Cell Transplantation Conditioned With Total Body Irradiation for Malignant Lymphoma: Increased Risk of Infectious Complications
Assessment of Prognostic Factors in Follicular Lymphoma Patients
A high dose chemoradiotherapy and peripheral blood stem cell support combined with the CD34^+-selection method in cyclin D1^+-mantle cell lymphoma
Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study
Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma : Japan Clinical Oncology Group study 9004
A Randomized Controlled Trial Investigating the Survival Benefit of Dose-Intensified Multidrug Combination Chemotherapy (LSG9) for Intermediate- or High-Grade Non-Hodgkin's Lymphoma : Japan Clinical Oncology Group Study 9002
NAD(P)H : quinone oxidoreductase 1 (NQ01) C609T polymorphism and the risk of eight cancers for Japanese
Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab
Cytotoxic large T-cell lymphoma with fulminant clinical course,CD8^+ and CD56^-phenotype, and its relation to Epstein-Barr virus:a report of two cases
Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese
Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine : a multicenter study
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab : A multicenter phase II study
Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-and low-intermediate risk, aggressive non-Hodgkin's lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG95

もっと見る

スポンサーリンク